Alkermes plc
IEFinancials
Valuation Metrics
Alkermes plc's Market Cap is $7.23B. At end of 2025 it was $4.61B. Ranked #1069 of 3,121 in US market (top 34%), #350 of 1,463 on NASDAQ (top 24%), #57 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $7.23B | US#1,069/3,121 Sec#57/266 |
| Revenue | $1.67B | US#1,551/3,121 Sec#40/266 |
| Net Income | $66M | US#1,776/3,121 Sec#59/266 |
| Total Assets | $4.39B | US#1,523/3,121 Sec#40/266 |
| Net Assets | $1.81B | US#1,322/3,121 Sec#41/266 |
| Employees | 2,050 | US#1,665/3,121 Sec#39/266 |
| Value | ||
| P/E | 109.37x | US#2,128/3,121 Sec#68/266 |
| P/B | 4.00x | US#2,091/3,121 Sec#126/266 |
| P/S | 4.34x | US#2,241/3,121 Sec#72/266 |
| EV/EBITDA | 38.03x | US#2,317/3,121 Sec#68/266 |
| FCF Yield | 3.06% | US#1,867/3,121 Sec#61/266 |
| Profitability | ||
| ROE | 3.66% | US#1,912/3,121 Sec#59/266 |
| ROA | 1.51% | US#1,783/3,121 Sec#67/266 |
| Op. Margin | 7.03% | US#1,840/3,121 Sec#68/266 |
| Revenue Growth | 10.79% | US#1,203/3,121 Sec#96/266 |
| Earnings Growth | -81.02% | US#1,839/3,121 Sec#52/266 |
| Financial Health | ||
| Debt Ratio | 142.91% | US#1,454/3,121 Sec#186/266 |
| Total Debt | $1.57B | US#1,310/3,121 Sec#36/266 |
| FCF | $222M | US#1,333/3,121 Sec#44/266 |
| Cash | $512M | US#1,060/3,121 Sec#56/266 |
| Current Ratio | 2.30x | US#1,082/3,121 Sec#214/266 |
| Net Debt/EBITDA | 4.87x | US#2,001/3,121 Sec#74/266 |
| Performance | ||
| 1Y Return | 51.98% | US#377/3,121 Sec#85/266 |
| 1M Return | -13.53% | US#1,823/3,121 Sec#146/266 |
| From 52W High | -22.06% | US#1,218/3,121 Sec#82/266 |
| 1Y MDD | -22.20% | US#864/3,121 Sec#39/266 |
| Trading | ||
| Volume | 5,329,584 shares | US#1,255/3,121 Sec#134/266 |
| Trading Value | $237M | US#1,195/3,121 Sec#90/266 |
| Per Share | ||
| EPS | $0.40 | US#1,930/3,121 Sec#61/266 |
| BPS | $10.85 | US#1,789/3,121 Sec#68/266 |
Company Info
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.